The Venous (Vein) Thrombosis drugs in development market research report provides comprehensive information on the therapeutics under development for Venous (Vein) Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Venous (Vein) Thrombosis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Venous (Vein) Thrombosis and features dormant and discontinued products.

GlobalData tracks 24 drugs in development for Venous (Vein) Thrombosis by 21 companies/universities/institutes. The top development phase for Venous (Vein) Thrombosis is preclinical with 14 drugs in that stage. The Venous (Vein) Thrombosis pipeline has 23 drugs in development by companies and one by universities/ institutes. Some of the companies in the Venous (Vein) Thrombosis pipeline products market are: Glycan Therapeutics, CarboMimetics and Tianjin Pharmaceuticals Group.

The key targets in the Venous (Vein) Thrombosis pipeline products market include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC, Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC, and Antithrombin III (ATIII or SERPINC1).

The key mechanisms of action in the Venous (Vein) Thrombosis pipeline product include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC Inhibitor with eight drugs in Phase I. The Venous (Vein) Thrombosis pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Venous (Vein) Thrombosis pipeline products market including Small Molecule, and Polysaccharide.

Venous (Vein) Thrombosis overview

Venous thromboembolism (VTE) is a condition characterized by the formation of blood clots in veins, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically manifests in deep veins, commonly in the lower leg, thigh, or pelvis, and can extend to the arms, particularly with intravenous central lines. Pulmonary embolism occurs when a detached clot travels to the lungs. With approximately 600,000 annual cases in the US, VTE is prevalent. Highest risk periods include major surgery, injury, or infections, where damaged veins and immobility contribute to clot formation. Symptoms include swelling, redness, and pain for DVT, while PE may present with sudden chest pain and shortness of breath.

For a complete picture of Venous (Vein) Thrombosis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.